Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 31;15(4):906.
doi: 10.3390/v15040906.

HLA Variation and SARS-CoV-2 Specific Antibody Response

Dawit Wolday  1   2 , Chun Yiu Jordan Fung  1   2 , Gregory Morgan  1   2   3 , Selina Casalino  1   2 , Erika Frangione  1   2 , Jennifer Taher  1   3 , Jordan P Lerner-Ellis  1   2   3
Affiliations
Review

HLA Variation and SARS-CoV-2 Specific Antibody Response

Dawit Wolday et al. Viruses. .

Abstract

Differences in SARS-CoV-2-specific immune responses have been observed between individuals following natural infection or vaccination. In addition to already known factors, such as age, sex, COVID-19 severity, comorbidity, vaccination status, hybrid immunity, and duration of infection, inter-individual variations in SARS-CoV-2 immune responses may, in part, be explained by structural differences brought about by genetic variation in the human leukocyte antigen (HLA) molecules responsible for the presentation of SARS-CoV-2 antigens to T effector cells. While dendritic cells present peptides with HLA class I molecules to CD8+ T cells to induce cytotoxic T lymphocyte responses (CTLs), they present peptides with HLA class II molecules to T follicular helper cells to induce B cell differentiation followed by memory B cell and plasma cell maturation. Plasma cells then produce SARS-CoV-2-specific antibodies. Here, we review published data linking HLA genetic variation or polymorphisms with differences in SARS-CoV-2-specific antibody responses. While there is evidence that heterogeneity in antibody response might be related to HLA variation, there are conflicting findings due in part to differences in study designs. We provide insight into why more research is needed in this area. Elucidating the genetic basis of variability in the SARS-CoV-2 immune response will help to optimize diagnostic tools and lead to the development of new vaccines and therapeutics against SARS-CoV-2 and other infectious diseases.

Keywords: COVID-19; HLA; MHC; SARS-CoV-2; antibody; genomics; immunoglobulin; polymorphism.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
HLA variation determines SARS-CoV-2-specific antibody response. In this example, we present different scenarios suggesting differential SARS-CoV-2-specific antibody response impacted by variation in the HLA class II molecule. (A) MHC-II molecule binding to SARS-CoV-2 peptides induces efficient CD4+ T cell and antibody response leading to viral neutralization, ADCC, and the death of SARS-CoV-2 infected cells. (B) Polymorphic MHC-II molecule binding to viral peptide fails to stimulate CD4+ T cells and results in low antibody titer, lack of ADCC, and ADP. Abbreviations: Ab: antibody; ADCC: antibody-dependent cellular (NK cell) cytotoxicity; ADP: antibody-dependent phagocytosis; HLA: human leukocyte antigen; MØ: macrophage; MHC: major histocompatibility complex; nAbs: neutralizing antibodies; TH0: CD4+ helper cells; TH: T helper; TFH: T follicular helper cells. Figure made using BioRender.
Figure 2
Figure 2
Heat-map showing the association between HLA variants and antibody responses or epitope binding affinity. Associations are depicted arbitrarily as high (scaled 1, yellow boxes), low (scaled 0.5, red boxes), or no association (scaled 0, dark-blue boxes). Gray boxes indicate undetermined values. References shown are for antibody response* or epitope binding affinity** studies.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. O’Driscoll M., Dos Santos G.R., Wang L., Cummings D.A.T., Azman A.S., Paireau J., Fontanet A., Cauchemez S., Salje H. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature. 2021;590:140–145. doi: 10.1038/s41586-020-2918-0. - DOI - PubMed
    1. Takahashi T., Ellingson M.K., Wong P., Israelow B., Lucas C., Klein J., Silva J., Mao T., Oh J.E., Tokuyama M., et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature. 2020;588:315–320. doi: 10.1038/s41586-020-2700-3. - DOI - PMC - PubMed
    1. Kullar R., Marcelin J.R., Swartz T.H., Piggott D.A., Macias Gil R., Mathew T.A., Tan T. Racial disparity of Coronavirus Disease 2019 in African American communities. J. Infect. Dis. 2020;222:890–893. doi: 10.1093/infdis/jiaa372. - DOI - PMC - PubMed
    1. Navaratnam A.V., Gray W.K., Day J., Wendon J., Briggs T.W.R. Patient factors and temporal trends associated with COVID-19 in-hospital mortality in England: An observational study using administrative data. Lancet Respir. Med. 2021;9:397–406. doi: 10.1016/S2213-2600(20)30579-8. - DOI - PMC - PubMed
    1. Bennett T.D., Moffitt R.A., Hajagos J.G., Amor B., Anand A., Bissell M.M., Bradwell K.R., Bremer C., Byrd J.B., Denham A., et al. Clinical Characterization and Prediction of Clinical Severity of SARS-CoV-2 Infection Among US Adults Using Data from the US National COVID Cohort Collaborative. JAMA Netw. Open. 2021;4:e2116901. doi: 10.1001/jamanetworkopen.2021.16901. - DOI - PMC - PubMed

Publication types

Grants and funding

-